First Author: O.Parkhomenko UKRAINE
Co Author(s): T. Gladush G. Parkhomenko A. Sergienko O. Parkhomenko S. Mogilevskyy
Back to previous
To investigate the efficacy of angioregimen of optical coherence tomography in diagnostics and monitoring of beginning stage of neoascular age related macular degeneration
Central polyclinic of ministry of internal affairs
There were 18 eyes (17 patients) with age related macular degeneration (ARMD) with drusenoid retinal pigment epithelial detachment (PED) and suspect of debut of choroidal neovascularistion (CNV) were included in the study. In addition to standard ophthalmological investigations to all the patients fluorescence angiography and angio-OCT on Swept-Source OCT Triton (Topcon, Japan) were performed at the beginnig of the study and then with 1 month interval. There were no intraretinal or subretinal excudation or clearly CNV detected on FA or OCT. The presence of active CNV was proved by negative anatomical dynamics (growth of CNV) on angio-OCT. To all the patients intravitreal injections of ranibizumab (Lucentis, Novartis Pharma, Switzerland) 0,5 mg in 0,05 ml with 1 month interval were performed untill CNV regression was achieved. For evaluation of effectiveness of treatment the average thickness of foveal region, best corrected visual acuity (BCVA) before and after treatment, presence of activity (perfusion) and regression of CNV on angio-OCT, quantity of injections needed for complete regression of CNV were estimated.
In 12 eyes of 11 patients type 1 (occult) CNV were detected. After the treatment positive anatomical result was achieved: absence of perfusion and regression of CNV, resolution of PED. Foveal thickness before treatment was 319 ± 76,78 mkm, and after treatment 263,19 ± 49,21 mkm (р<0,05). Mean BCVA was 0,74 ± 0,12 before treatment and 0,75 ± 0,15 after treatment (p>0,05). Mean quantity of injections was 3,75 ± 1,66.
Angio-OCT technology allows to visualize type 1 CNV noninvasively on beginning stage of neovascular ARMD before development of exudative changes of retina and to control the regression of neovascular vessels during treatment.